INVESTIGADORES
PERAL Maria De Los Angeles
artículos
Título:
ntensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina
Autor/es:
CHALHA ROSSANA; LUIS RUIZ MEDINA; EUGENIA S. ORTEGA; MARCELO F. MORALES; ALEXIA GEORGE; FRANCISCO BARREIRO; CESAR MANCILLA; SYLVIA D AMATO; GUILLERMO BARRENECHEA; DANIEL G. GOROSO; PERAL DE BRUNO MARÍA
Revista:
AMERICAN JOURNAL OF THERAPEUTICS
Editorial:
LIPPINCOTT WILLIAMS & WILKINS
Referencias:
Lugar: Philadelphia; Año: 2021
ISSN:
1075-2765
Resumen:
use for COVID-19 treatment is not conclusive. How-ever, it encouraged its utilization in controlled clinicaltrials. At June 2021, there were 65 studies registered athttps://www.ClinicalTrials.gov and 45 studies listedat https://ClinicalTrials.gov/ct2/who_table about thesafety and effectiveness of ivermectin in subjects withCOVID-19, of which 16 studies have been completed(for COVID-19 treatment). Most of these studies onivermectin repositioning came from developing coun-tries like ours, Argentina, with limited access to vac-cines. These emergent economies have the need to findsupportive therapies that are synergistic or alternativesto contain the spread of the disease and deter thehealth systems?collapse